Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer

Cancer Prevention Research

Volumn 6, Issue 6, 2013, Pages 577-584

  Miller, Jessica A ^a   Lang, Julie E ^a,c   Ley, Michele ^a   Nagle, Ray ^a   Hsu, Chiu Hsieh ^a,b   Thompson, Patricia A ^a   Cordova, Catherine ^a   Waer, Amy ^a,c   Chow, H H Sherry ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CASPASE 3; CYCLIN D1; DRUG METABOLITE; INTERLEUKIN 6; KI 67 ANTIGEN; LEPTIN; LIMONENE; PERILLIC ACID; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; BLOATING; BREAST; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DISPOSITION; FEMALE; FLATULENCE; HEARTBURN; HUMAN; HUMAN TISSUE; HYPOCHLOREMIA; HYPOKALEMIA; HYPOTHESIS; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PRURITUS; REDUCTION; TASTE DISORDER; TREATMENT DURATION; VOMITING; XEROSTOMIA;

ANTICARCINOGENIC AGENTS; BREAST; BREAST NEOPLASMS; CASPASE 3; CITRUS; CYCLIN D1; CYCLOHEXENES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; INTERVENTION STUDIES; MIDDLE AGED; MONOTERPENES; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; TERPENES; TISSUE DISTRIBUTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 84878858043     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0452     Document Type: Article

References (40)

1. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 2009; 1016: 384-98.
2. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res 2010; 36: 696-706.
3. Kelloff GJ, Lubet RA, Lieberman R, Eisenhauer K, Steele VE, Crowell JA, et al. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1998;71:65-78. (Pubitemid 28087144)
4. Cuzick J. Chemoprevention of breast cancer. Breast Cancer 2008; 151: 10-6.
5. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 36425: 2381-91.
6. Elson CE, Maltzman TH, Boston JL, Tanner MA, Gould MN. Anti-carcinogenic activity of d-limonene during the initiation and promotion/progression stages of DMBA-induced rat mammary carcinogenesis. Carcinogenesis 1988;92:331-2. (Pubitemid 18038001)
7. Maltzman TH, Hurt LM, Elson CE, Tanner MA, Gould MN. The prevention of nitrosomethylurea-induced mammary tumors by d-limonene and orange oil. Carcinogenesis 1989;104:781-3. (Pubitemid 19101303)
8. Gould MN, Moore CJ, Zhang R, Wang B, Kennan WS, Haag JD. Limonene chemoprevention of mammary carcinoma induction following direct in situ transfer of v-Ha-ras. Cancer Res 1994; 5413: 3540-3.
9. Elegbede JA, Elson CE, Tanner MA, Qureshi A, Gould MN. Regression of rat primary mammary tumors following dietary d-limonene. J Natl Cancer Inst 1986;762:323-5. (Pubitemid 16130014)
10. Haag JD, Lindstrom MJ, Gould MN. Limonene-induced regression of mammary carcinomas. Cancer Res 1992; 5214: 4021-6.
11. Azzoli CG, Miller VA, Ng KK, Krug LM, Spriggs DR, Tong WP, et al. A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol 2003;516:493-8. (Pubitemid 36791675)
12. Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, et al. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 2000;68:3071-80. (Pubitemid 30637730)
13. Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R, et al. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol 2003;525:361-6. (Pubitemid 37363607)
14. Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, et al. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 2000;62:390-6. (Pubitemid 30111455)
15. Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, et al. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother Pharmacol 2004;544:368-76. (Pubitemid 39304432)
16. Vigushin DM, Poon GK, Boddy A, English J, Halbert GW, Pagonis C, et al. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol 1998;422:111-7. (Pubitemid 28267291)
17. Crowell PL, Kennan WS, Haag JD, Ahmad S, Vedejs E, Gould MN. Chemoprevention of mammary carcinogenesis by hydroxylated derivatives of d-limonene. Carcinogenesis 1992; 137: 1261-4.
18. Miller JA, Thompson PA, Hakim IA, Lopez AM, Thomson CA, Chew W, et al. Safety and feasibility of topical application of limonene as a massage oil to the breast. J Cancer Ther 2012; 3: 749-54.
19. Miller JA, Hakim IA, Chew W, Thompson P, Thomson CA, Chow HH. Adipose tissue accumulation of d-limonene with the consumption of a lemonade preparation rich in d-limonene content. Nutr Cancer 2010; 626: 783-8.
20. Miller JA, Hakim IA, Thomson C, Thompson P, Chow HH. Determination of d-limonene in adipose tissue by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 8701: 68-73.
21. Chow HH, Salazar D, Hakim IA. Pharmacokinetics of perillic acid in humans after a single dose administration of a citrus preparation rich in d-limonene content. Cancer Epidemiol Biomarkers Prev 2002;1111:1472-6. (Pubitemid 35340387)
22. Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, et al. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer 2010; 10: 639.
23. United States. Environmental Protection Agency. Prevention, Pesticides, Toxic Substances: Exposure and Risk Assessment on Lower Risk Pesticide Chemicals: D-limonene: U.S. Environmental Protection Agency, Office of Prevention, Pesticides and Toxic Substances. 2005.
24. Karlson J, Borg-Karlson AK, Unelius R, Shoshan MC, Wilking N, Ringborg U, et al. Inhibition of tumor cell growth by monoterpenes in vitro: evidence of a Ras-independent mechanism of action. Anticancer Drugs 1996;74:422-9. (Pubitemid 26249196)
25. Hardcastle IR, Rowlands MG, Barber AM, Grimshaw RM, Mohan MK, Nutley BP, et al. Inhibition of protein prenylation by metabolites of limonene. Biochem Pharmacol 1999;577:801-9. (Pubitemid 29094551)
26. Crowell PL, Ren Z, Lin S, Vedejs E, Gould MN. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 1994;478:1405-15. (Pubitemid 24130935)
27. Musgrove EA, LeeCS, Buckley MF, Sutherland RL. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A 1994;9117:8022-6. (Pubitemid 24253878)
28. Alle KM, Henshall SM, Field AS, Sutherland RL. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 1998;44:847-54. (Pubitemid 28183384)
29. Gillett CE, Lee AH, Millis RR, Barnes DM. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol 1998; 1844: 396-400.
30. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK, Sutherland RL. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993;136:3577-87. (Pubitemid 23157295)
31. Bardon S, Picard K, Martel P. Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutr Cancer 1998;321:1-7. (Pubitemid 28519235)
32. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;2322:5108-16. (Pubitemid 46224019)
33. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;112 Pt 2:951s-8s. (Pubitemid 40111111)
34. Jirtle RL, Haag JD, Ariazi EA, Gould MN. Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 1993;5317:3849-52. (Pubitemid 23267674)
35. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 2010; 119: 1133-46.
36. Yoon WJ, Lee NH, Hyun CG. Limonene suppresses lipopolysaccharide-induced production of nitric oxide, prostaglandin E2, and proinflammatory cytokines in RAW 264.7 macrophages. J Oleo Sci 2010; 598: 415-21.
37. Evans DL, Miller DM, Jacobsen KL, Bush PB. Modulation of immune responses in mice by d-limonene. J Toxicol Environ Health 1987;201-2:51-66. (Pubitemid 17013629)
38. Hamada M, Uezu K, Matsushita J, Yamamoto S, Kishino Y. Distribution and immune responses resulting from oral administration of D-limonene in rats. J Nutr Sci Vitaminol 2002;482:155-60. (Pubitemid 34733448)
39. Raphael TJ, Kuttan G. Immunomodulatory activity of naturally occurring monoterpenes carvone, limonene, and perillic acid. Immunopharmacol Immunotoxicol 2003;252:285-94. (Pubitemid 36597423)
40. Del Toro-Arreola S, Flores-Torales E, Torres-Lozano C, Del Toro-Arreola A, Tostado-Pelayo K, Guadalupe Ramirez-Duenas M, et al. Effect of D-limonene on immune response in BALB/c mice with lymphoma. Int Immunopharmacol 2005;55:829-38. (Pubitemid 40381117)